KV Pharmaceutical Smacked With Class-Action Lawsuit

Image via

Big beard, big problems: KV's former CEO Marc Hermelin

​As if KV Pharmaceutical wasn't roiling with enough intrigue already: In addition to criminal convictions, a wave of firings, bickering executives, and legal wrangling, the Bridgeton-based drug company now must defend itself against a class-action lawsuit.

The suit, filed yesterday in federal court, is being brought by folks who purchased KV stock last Spring. The plaintiffs allege that the company was less than up-front about its "financial well-being, business operations, and prospects" at that time.

Specifically, the plaintiffs claim, KV failed to disclose that the FDA hadn't granted the company exclusive distribution rights to Makena -- a hormone injection used by pregnant women to lower the risk of premature birth.

Nor, they allege, did KV level with investors about Makena's $1500 price tag per dosage, and how that would "decrease meaningful demand."

Check out the complaint below. Class Action Complaint v. KV Pharm